These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 4271633)

  • 21. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
    Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN
    Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
    Levi M; Roem D; Kamp AM; de Boer JP; Hack CE; ten Cate JW
    Thromb Haemost; 1993 Feb; 69(2):141-6. PubMed ID: 7681223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of human platelet membrane fibrinogen receptors by immunochemical techniques.
    Kornecki E; Tuszynski GP; Niewiarowski S
    Haematologia (Budap); 1984; 17(3):387-98. PubMed ID: 6100105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of staphylokinase on platelet aggregation.
    Suehiro A; Oura Y; Ueda M; Kakishita E
    Thromb Haemost; 1993 Nov; 70(5):834-7. PubMed ID: 7510426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
    Noll G; Lämmle B; Duckert F
    Thromb Haemost; 1984 Jul; 51(3):334-7. PubMed ID: 6238441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
    Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE
    Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on platelet proteins. IX. The identity of fibrinogen.
    James HL; Ganguly P
    Biochim Biophys Acta; 1973 Dec; 328(2):448-55. PubMed ID: 4272948
    [No Abstract]   [Full Text] [Related]  

  • 29. Isolation and properties of a soluble trypsin inhibitor from platelets and its interaction with a prothrombin derivative.
    Woelk H; Nagel W; Weber E
    Acta Univ Carol Med Monogr; 1972; 53():157-63. PubMed ID: 4275438
    [No Abstract]   [Full Text] [Related]  

  • 30. Platelets and plasminogen activation.
    Loscalzo J; Pasche B; Ouimet H; Freedman JE
    Thromb Haemost; 1995 Jul; 74(1):291-3. PubMed ID: 8578474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical studies on a low molecular weight antiplasmin of human blood.
    Mui PT; Ganguly P
    Arch Biochem Biophys; 1977 Feb; 179(1):166-73. PubMed ID: 139125
    [No Abstract]   [Full Text] [Related]  

  • 32. On the kinetics of the reaction between human antiplasmin and plasmin.
    Wiman B; Collen D
    Eur J Biochem; 1978 Mar; 84(2):573-8. PubMed ID: 147769
    [No Abstract]   [Full Text] [Related]  

  • 33. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma.
    Wiman B; Collen D
    Eur J Biochem; 1977 Aug; 78(1):19-26. PubMed ID: 21075
    [No Abstract]   [Full Text] [Related]  

  • 34. Plasmin-antiplasmin complex formation during defibrase infusion in man.
    Collen D; Verstraete M
    Thromb Res; 1977 Sep; 11(3):417-20. PubMed ID: 144333
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasmatic and thrombocytic anti-plasmins and anti-activators. II.
    den Ottolander GJ; Leijnse B; Cremer-Elfrink HM
    Thromb Diath Haemorrh; 1969 Feb; 21(1):26-34. PubMed ID: 4237623
    [No Abstract]   [Full Text] [Related]  

  • 36. The plasmin inhibition by synthetic antifibrinolytic agents in relation to the type of substrate.
    Lukasiewicz H; Niewiarowski S; Worowski K; Lipiński B
    Biochim Biophys Acta; 1968 Jul; 159(3):503-8. PubMed ID: 4232070
    [No Abstract]   [Full Text] [Related]  

  • 37. [Fibrinolytic activity of platelets].
    Dechavanne M; Viala JJ; Arnaud P; Creyssel R; Lagarde M
    Nouv Presse Med; 1973 Mar; 2(10):653. PubMed ID: 4267319
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinetic properties of the primary inhibitor of plasmin from human plasma.
    Christensen U; Clemmensen I
    Biochem J; 1977 May; 163(2):389-91. PubMed ID: 141280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Method of determination of blood tolerance to plasmin].
    Gritsiuk AI
    Lab Delo; 1968; 10():604-7. PubMed ID: 4184082
    [No Abstract]   [Full Text] [Related]  

  • 40. [A new method for the determination of plasmin activity, using I-131-labelled casein as substrate].
    KUROYANAGI T; KURISU A
    Nisshin Igaku Jpn J Med Prog; 1962 Mar; 49():183-8. PubMed ID: 14460807
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.